Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

470 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study.
Kinoshita T, Hatake K, Yamamoto K, Higuchi Y, Murakami S, Terui Y, Yokoyama M, Maruyama D, Makita S, Hida Y, Saito T, Tobinai K. Kinoshita T, et al. Among authors: hatake k. Jpn J Clin Oncol. 2021 Jan 1;51(1):70-77. doi: 10.1093/jjco/hyaa169. Jpn J Clin Oncol. 2021. PMID: 33029633 Free PMC article. Clinical Trial.
[Proteasome inhibitors].
Hatake K, Mishima Y, Terui Y. Hatake K, et al. Gan To Kagaku Ryoho. 2004 Jul;31(7):999-1002. Gan To Kagaku Ryoho. 2004. PMID: 15272575 Review. Japanese.
[Rituximab and hematological malignancy].
Hatake K, Mishima Y, Terui Y. Hatake K, et al. Nihon Rinsho. 2004 Jul;62(7):1321-4. Nihon Rinsho. 2004. PMID: 15283150 Review. Japanese.
Combination chemotherapy (cyclophosphamide, doxorubicin, and vincristine with continuous-infusion cisplatin and etoposide) and radiotherapy with stem cell support can be beneficial for adolescents and adults with estheisoneuroblastoma.
Mishima Y, Nagasaki E, Terui Y, Irie T, Takahashi S, Ito Y, Oguchi M, Kawabata K, Kamata S, Hatake K. Mishima Y, et al. Among authors: hatake k. Cancer. 2004 Sep 15;101(6):1437-44. doi: 10.1002/cncr.20471. Cancer. 2004. PMID: 15368332 Free article.
INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
Yokota A, Kimura S, Masuda S, Ashihara E, Kuroda J, Sato K, Kamitsuji Y, Kawata E, Deguchi Y, Urasaki Y, Terui Y, Ruthardt M, Ueda T, Hatake K, Inui K, Maekawa T. Yokota A, et al. Among authors: hatake k. Blood. 2007 Jan 1;109(1):306-14. doi: 10.1182/blood-2006-03-013250. Epub 2006 Sep 5. Blood. 2007. PMID: 16954504 Free article.
470 results